shstuebingen Current page: 16

With a population of around 1.4 billion, the People’s Republic of China is an enormously attractive market for medtech and life-science products. For foreign firms, this presents not only great opportunities but risks as well. By: Dr André Zimmermann, partner at Tübingen-based industry investor SHS. He has developed global connections in the medical technology sector […]

ZDF TV reports in its heute Sendung (from min. 07:32) at prime time about our portfolio company GNA Biosolutions GmbH. The company has received emergency approval for its point-of-care test, which enables detection for COVID19 within 40 minutes.

German molecular diagnostics startup GNA Biosolutions has received Emergency Use Authorization (Sonderzulassung) from the German Federal Institute for Drugs and Medical Devices (BfArM) for the GNA Octea SARS-CoV-2 Test System. The new technology developed by GNA Biosolutions enables decentralized COVID-19 rapid tests in approximately 40 minutes without sacrificing sensitivity.

The Tübingen-based SHS Gesellschaft für Beteiligungsmanagement mbH invests from its SHS V fund in the Swiss-German specialty pharmaceuticals company Develco Pharma.

Every year, counterfeit medicines cause harm to many patients, particularly in developing countries. This problem is being tackled by a joint project of the Tübingen-based Difäm and the Ecumenical Pharmaceutical Network (EPN) that aims to detect counterfeit medicines in developing countries with the help of local analytics. To this end, local centres are provided with […]

Positive economic news is rare in times of crisis. This makes this news from Graz all the more pleasing: an order worth millions of euros gives SHS portfolio company Tyromotion a positive outlook for the future.

Tübingen-based industry investor SHS acquires minority share in formulation specialist Develco Pharma Develco specializes in the development, approval and production of innovative and generic specialty drugs and offers a unique and broad set of formulation technologies for orally administered medicines with specific substance-release profiles Develco operates a state-of-the-art production facility of its own in Germany […]

While the EU is significantly raising approval hurdles with the MDR, the US is putting medtech innovations in the fast lane with the Breakthrough Devices Program By: Dr André Zimmermann, partner at Tübingen-based industry investor SHS. He has developed global connections in the medical technology sector as a business development expert. Putting the brakes on […]

Unquote reports on the sale of our portfolio company puracon to the precision machining business Klingel medical metal, which is a portfolio company of IK Investment Partners.

SHS Gesellschaft für Beteiligungsmanagement mbH, based in Tübingen, is selling its shares in puracon GmbH to Klingel medical metal GmbH, a portfolio company of IK Investment Partners. With 600 employees, Klingel Group is one of the leading companies in the field of precision machining of high-strength materials such as stainless steel and titanium for the […]

The trade magazine of going public portrays SHS (page 50-51) as one of the oldest players in the financing of German life sciences companies, start-ups and SMEs, with a focus on medical technology, diagnostics, suppliers and digital health.

Coronavirus, digitalisation, MDR, Brexit – companies in the medical technology sector face major, capital-intensive challenges. What is key at this stage? By: Dr André Zimmermann, partner at Tübingen-based industry investor SHS. He has developed global connections in the medical technology sector as a business development expert. Coronavirus takes its toll It is autumn and, as […]